Amgen ' s Sotorasib Granted Breakthrough Therapy Designation For Advanced Or Metastatic Non-Small Cell Lung Cancer Patients With KRAS G12C Mutation

THOUSAND OAKS, Calif., Dec. 8, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for its investigational...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials